Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy

Journal:

Nature Communications

Published:

2025-12-17

DOI:

10.1038/s41467-025-66132-w

Affiliations:

5

Authors:

20

Go to article

Institutions	Authors	Share
Aethon Therapeutics, United States of America (USA)	13.000000 13.000000	0.65
NYU Laura and Isaac Perlmutter Cancer Center, United States of America (USA)	3.000000	0.15
Apple Tree Partners (ATP), United States of America (USA)	2.000000	0.10
NYU Langone Health, United States of America (USA)	2.000000	0.10

Interested in Oncology and Carcinogenesis?